Evidence map›Paper›PMID 28521060›Full record

ArticleSchizophrenia bulletin2018

Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis.

Paolo Fusar-Poli, Andrea De Micheli, Marco Cappucciati, Grazia Rutigliano, Cathy Davies, Valentina Ramella-Cravaro, Dominic Oliver, Ilaria Bonoldi, Matteo Rocchetti, Lauren Gavaghan and 2 more

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Schizophrenia bulletin, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Early language measures associated with later psychosis features in 22q11.2 deletion syndrome.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2020
    Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Paolo Fusar-PoliEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Andrea De MicheliEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Marco CappucciatiEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Grazia RutiglianoEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Cathy DaviesEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Valentina Ramella-CravaroEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Dominic OliverEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Ilaria BonoldiEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Matteo RocchettiEarly Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, King's College London, Institute of Psychiatry Psychology and Neuroscience, London, UK.
Lauren GavaghanOASIS Service, South London and the Maudsley NHS Foundation Trust, London, UK.
Rashmi PatelOASIS Service, South London and the Maudsley NHS Foundation Trust, London, UK.
Philip McGuireOASIS Service, South London and the Maudsley NHS Foundation Trust, London, UK.
King's College London · GBSouth London and Maudsley NHS Foundation Trust · GB

Funding

Medical Research Council MR/S003118/1
6 · The paper itself

Abstract

Background: The diagnostic and prognostic significance of the DSM-5-defined Attenuated Psychosis Syndrome (DSM-5-APS) in individuals undergoing an ultra high risk (UHR) clinical assessment for suspicion of psychosis risk is unknown. Methods: Prospective cohort study including all consecutive help-seeking individuals undergoing both a DSM-5-APS and a Comprehensive Assessment of At Risk Mental States (CAARMS 12/2006) assessment for psychosis risk at the Outreach and Support in South London (OASIS) UHR service (March 2013-April 2014). The diagnostic significance of DSM-5-APS was assessed with percent overall agreement, prevalence bias adjusted kappa, Bowker's test, Stuart-Maxwell test, residual analysis; the prognostic significance with Cox regression, Kaplan-Meier failure function, time-dependent area under the curve (AUC) and net benefits analysis. The impact of specific revisions of the DSM-5-APS was further tested. Result: In 203 help-seeking individuals undergoing UHR assessment, the agreement between the DSM-5-APS and the CAARMS 12/2006 was only moderate (kappa 0.59). Among 142 nonpsychotic cases, those meeting DSM-5-APS criteria had a 5-fold probability (HR = 5.379) of developing psychosis compared to those not meeting DSM-5-APS criteria, with a 21-month cumulative risk of psychosis of 28.17% vs 6.49%, respectively. The DSM-5-APS prognostic accuracy was acceptable (AUC 0.76 at 24 months) and similar to the CAARMS 12/2006. The DSM-5-APS designation may be clinically useful to guide the provision of indicated interventions within a 7%-35% (2-year) range of psychosis risk. The removal of the criterion E or C of the DSM-5-APS may improve its prognostic performance and transdiagnostic value. Conclusions: The DSM-5-APS designation may be clinically useful in individuals accessing clinical services for psychosis prevention.

Indexed as

Diagnostic and Statistical Manual of Mental DisordersAdolescentAdultCross-Sectional StudiesFemaleHumansLondonLongitudinal StudiesMaleMental Health ServicesPredictive Value of TestsProdromal SymptomsPrognosisPsychiatric Status Rating ScalesPsychotic DisordersRisk Assessment

Identifiers

PMID28521060
PMCPMC5814820
OpenAlexW2609460073

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.